Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.
The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.
TScan Therapeutics reported positive initial data from Cohort C of its ALLOHA™ Phase 1 study of TSC-101 in patients with blood cancers undergoing allogeneic stem cell transplant. TSC-101, made with a commercial-ready process, led to complete donor chimerism in 11 of 14 patients about three weeks after the first infusion, an early signal linked to lower relapse risk. All but one Cohort C patient (93%) showed decreasing recipient chimerism, indicating effective targeting of residual disease, and no relapses have been observed to date. Safety in Cohort C remained manageable, with fewer acute graft-versus-host disease events than the control group and only one grade 1 cytokine release syndrome event resolving after TSC-101. Earlier ALLOHA data showed 100% of TSC-101–treated patients relapse-free at three years in a small subset versus none on control, helping justify a pivotal Phase 3 ALLOHA-2™ trial targeting relapse-free survival. The company plans to start this Phase 3 trial in Q2 2026 and holds enough cash, $128 as of March 31, 2026, to fund operations into the second half of 2027.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
TScan Therapeutics, Inc. reported an insider Form 4 showing an award of 67,000 non-qualified stock options linked to its common stock. The options were granted to Dr. Stephen R. Biggar, who serves on the board, with a strike price of $0.9946 per share and expiration on May 19, 2036.
The options vest on the earlier of the first anniversary of the May 20, 2026 grant date or the next annual stockholder meeting, subject to Dr. Biggar’s continued board service. Under Baker Bros. Advisors LP policies, Dr. Biggar does not retain economic rights in these securities; related Baker funds instead hold an indirect proportionate pecuniary interest, and Baker-affiliated entities disclaim beneficial ownership beyond that interest.
TScan Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase authorized voting common stock from 300,000,000 to 600,000,000 shares, and the amendment became effective upon filing in Delaware on May 20, 2026.
Katina Dorton and R. Keith Woods were elected as Class II directors to serve until the 2029 annual meeting. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved an adjournment proposal, though adjournment was not needed.
TScan Therapeutics director Keith Woods received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. All 67,000 underlying shares vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options for 67,000 shares directly.
TScan Therapeutics director Garry A. Nicholson received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036. They vest in full on the earlier of May 20, 2027 or the next annual stockholder meeting, subject to his continued service.
TScan Therapeutics director Gabriela Gruia received a grant of stock options as part of her compensation. The award covers 67,000 options to buy Voting Common Stock at an exercise price of $0.9946 per share and expires on May 20, 2036.
According to the terms, these options will vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, provided she continues in service through that date. This filing reflects an equity grant, not an open‑market purchase or sale of shares.
TScan Therapeutics director Katina Dorton received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036.
The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, as long as she continues in service. After this grant, she holds 67,000 options directly, and there were no reported share purchases or sales in this filing.
TScan Therapeutics director Barbara Klencke received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. The entire grant will vest and become exercisable upon the earlier of May 20, 2027 or the company’s next annual stockholder meeting, provided she continues serving the company through that date. Following this grant, she holds options on 67,000 shares directly.
Biotechnology Value Fund, L.P. and affiliated reporting persons amended their Schedule 13G/A to disclose shared beneficial ownership and exercisable pre-funded warrants in TScan Therapeutics. As of March 31, 2026, the Reporting Persons held Pre-Funded Warrants exercisable for an aggregate of 8,784,348 shares, with exercise limited by a 9.99% blocker.
The filing states BVF beneficially owned 3,014,267 shares (5.4%), BVF2 beneficially owned 1,868,548 shares (3.3%), and Trading Fund OS beneficially owned 560,400 shares (1.0%). Aggregated positions are reported as 5,578,288 shares (9.99%) for Partners, BVF Inc., and Mr. Lampert; BVF GPH may be deemed to own 4,882,815 shares (8.7%). The filing cites 52,625,035 shares outstanding as of February 27, 2026 and notes 3,199,687 shares issued on March 27, 2026 upon prior exercises; 13,998 shares remain issuable under the Pre-Funded Warrants within the blocker limit.
TScan Therapeutics, Inc. reported a net loss of $28.7 million for the quarter ended March 31, 2026, compared with $34.1 million a year earlier, as research and development spending declined.
Collaboration and license revenue from its Amgen partnership was $982,000, down from $2.2 million, reflecting timing of research activities. Research and development expenses fell to $21.9 million from $29.8 million, mainly due to lower laboratory, facility and clinical costs after prioritizing its hematologic malignancy program.
The company ended the quarter with $128.1 million in cash and cash equivalents and total cash, cash equivalents and restricted cash of $133.1 million. Management believes this will fund its current operating plan into the second half of 2027 as it advances TCR-T cell therapy candidates, including lead program TSC-101 for acute myeloid leukemia and myelodysplastic syndrome.